|
|
Velosef (Cephradine) Suspension
|
 |
Systemic anti-infective
|
 |
Antibiotic
|
 |
Susceptible infections of respiratory, urinary tract, ear, skin and soft tissue
|
 |
Children: 25 to 50 mg/kg (2.2 lbs) in 2 to 4 divided doses. Otitis media: 75 to 100 mg/kg a day in 2 to 4 divided doses.
|
 |
Category B
|
 |
Diarrhea, GI upset, skin rash, nausea, vomiting, vaginal itching or discharge, severe allergic reaction
|
Pregnancy Risk Categories defined:
A: Studies in pregnant women failed to show a risk to the fetus in the first
trimester - with no evidence of risk in the later trimesters.
B: Animals studies indicate no adverse effect to the fetus, but there are no adequate,
clinical studies in pregnant women.
C: Animal studies have shown an adverse effect on the fetus, but there are no adequate,
clinical studies in humans. Despite potential risks, the drug may be useful in pregnant
women.
D: There is evidence of risk to the human fetus, but the potential benefits of use in
pregnant women may be acceptable, despite potential risks.
X: Studies in animals or humans show fetal abnormalities, or adverse reaction reports
indicate evidence of fetal risk. Warning: the risks involved clearly outweigh any
potential benefit from using the drug in pregnant women, regardless of trimester.
NR: Not rated (i.e., no information available at this time as to the potential
risks or benefits).
|
| | |
If you want your friend to read or know about this article, Click here
 |
|
|
